Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in distal convoluted tubule cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16300
Sealed predictions
- PLCL1 in dopamine neurons, braak+0.11 (p 0.787) → +0.55 (p 0.122)receipt 16309
- PLCL1 in oligodendrocytes, braak+0.52 (p 0.150) → -0.26 (p 0.493)receipt 16308
Swarm cases
receipt 16309: PLCL1 in dopamine neurons, braak
- power
- full sample +0.17 (p 0.509, n 18), 95% CI -0.33 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.12 (p 0.633, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.15 (p 0.561, n 18). could be the mix.
- skeptic
- leave-one-out range +0.06 to +0.30, sign flips 0; without severely affected donors +0.17 (p 0.509, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PLCL1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 16308: PLCL1 in oligodendrocytes, braak
- power
- full sample +0.18 (p 0.471, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.19 (p 0.460, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.26 (p 0.306, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.29, sign flips 0; without severely affected donors +0.18 (p 0.471, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PLCL1 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts